Publications by authors named "Juthamas Prawjaeng"

Claim this Profile
O
Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis.
Sarayuth Khuntha, Juthamas Prawjaeng, Kunnatee Ponragdee, Oranee Sanmaneechai, Varalak Srinonprasert

Appl Health Econ Health Policy· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand.
Tanawan Kongmalai, Juthamas Prawjaeng, Phorntida Hadnorntun, Pattara Leelahavarong, Usa Chaikledkaew

Pharmacoecon Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand.
Natthakan Chitpim, Pattara Leelahavarong, Juthamas Prawjaeng, Sakditat Ittiphisit, Varalak Srinonprasert

Sci Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis.
Phorntida Hadnorntun, Juthamas Prawjaeng, Tanawan Kongmalai, Phakamas Tanvijit, Chuenchom Chueluecha

BMJ Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.
Yi Wang, Nantasit Luangasanatip, Wirichada Pan-Ngum, Wanrudee Isaranuwatchai, Juthamas Prawjaeng

Eur J Health Econ· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
Juthamas Prawjaeng, Pattara Leelahavarong, Nuttakarn Budtarad, Songyot Pilasant, Chonticha Chanjam

BMC Health Serv Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Binding and neutralizing antibody levels and vaccine efficacy/effectiveness compared between heterologous and homologous primary series COVID-19 vaccination: A systematic review and meta-analysis.
Nasikarn Angkasekwinai, Juthamas Prawjaeng, Pattara Leelahavarong, Sarayuth Khuntha, Chatkamol Pheerapanyawaranun

Asian Pac J Allergy Immunol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Data-Driven Analysis of the Economic Cost of Non-Pharmaceutical Interventions: A Cross-Country Comparison of Kenya, Singapore, and Thailand.
Jamaica Briones, Yi Wang, Juthamas Prawjaeng, Hwee Lin Wee, Angela Kairu

Int J Public Health· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.
Chris Painter, Wanrudee Isaranuwatchai, Juthamas Prawjaeng, Hwee Lin Wee, Brandon Wen Bing Chua

Appl Health Econ Health Policy· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
Huey Yi Chong, Yi Heng Lim, Juthamas Prawjaeng, Wichittra Tassaneeyakul, Zahurin Mohamed

Pharmacogenet Genomics· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis